Austrian start-up Rebel Meat presented its hybrid meat balls during the EFIB 2019 conference in Brussels.
Source: EFIB 2019

Manufacturers are keen to get involved in the alternative meat market. Investors and incubators are pushing forward start-ups.

Mosa Meat aims at producing a cultured meat hamburger by 2022. Source: Mosa Meat

A first wave of cultured meat companies is pushing forward. European start-ups such as Mosa Meat and Peace of Meat are part of the game.

Austrian Phagomed wants to close a Series A financing in 2020. The start-up is working on phage-based treatments as a new alternative to antibiotics.

The new Dewpoint building at Boston harbour  a new area for biotech companies, Photo: Sascha Karberg

It’s a discovery that revolutionises our fundamental understanding of cells. Tiny droplets called condensates that form through weak interactions between proteins and RNA are at the heart of many key biological processes. Dewpoint Therapeutics – the first start-up to harness the basic research for a new therapeutic platform technology – is now opening a facility in the German capital Berlin.

New treatments against resistant Gram-negative bacteria, such as Pseudomonas aeruginosa, are the focus of a deal that Swiss pharma company Roche signed with US-based biotech company Forge Therapeutics in March. Source: CDC

With the coronavirus pandemic mounting, experts are warning of AMR as being the next, hidden crisis. 

Foto: ArtTower auf Pixabay

FGK Clinical Research GmbH opens a branch office in Berlin this month. The Berlin office will support the operative units at the German headquarters in Munich.

A single human stem-cell derived neuron (red) growing into itself on an island of astrocytes (blue). Such minimalist 'autapse' systems, which enable a highly standardised read-out of synaptic funktion for disease modeling and drug testing, are in co-development at the MPI for Experimental Medicine and Life & Brain GmbH. Picture: Dr. Ali Shaib/MPI for Experimental Medicine Göttingen

Dreams of simple, reliable and scalable processes for the much-hyped cell therapy market have generated demand for cost-effective, GMP-compliant manufacturing methods. The drug-screening market is also hungry for material that will allow the establishment of human cell disease models. A growing number of companies are now trying to coax induced pluripotent stem cells (iPSCs) into specific cells needed for clinical trials. Others are seeking the same goal through direct transdifferentiation protocols. What method will prove superior?

Despite the threat of a looming climate catastrophe, low oil prices and giant industrial conglomerates addicted to fossil resources continue to stifle industrial biotechnology products and innovation. The European Biotechnology Network is now providing a foot up for companies that want to help themselves by launching three very different projects aimed at pushing the bioeconomy forward.

Enzymes have been used widely for years to bleach textiles or shrink wool. However, the clothing sector is one of the world’s most polluting industries. And now fashion labels are turning increasingly to sustainable biofabrication and biotech-inspired methods to help lower the environmental footprint of their products.

Global overview on regulatory approaches implemented or discussed in different countries (Status: September 2019), Picture: Samynandpartners/Wikimed

After years of regulatory deadlock concerning political decision making on genome-edited and genetically targeted mutational breeding, the European Council has demanded that the European Commission regulate new plant breeding techniques (NBT), such as oligonucleotid-directed mutagenesis (ODM), gene scissors (CRISPR), and others.